Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Zoledronate Maintains Bone Loss After Denosumab Discontinuation

Key clinical point: A single intravenous infusion of zoledronate given 6 months after a denosumab injection prevents bone loss for at least 2 years independently of the rate of bone turnover.

Major finding: At 24 months, lumbar spine bone mineral density returned to baseline in the zoledronate group, but decreased in the denosumab group by 4.82% (P less than .001) from the 12‐month value. The difference in lumbar spine bone mineral density changes between the two groups from month 12 to 24, the primary endpoint of the study, was statistically significant (P = .025), as was the difference in changes of femoral neck bone mineral density (P = .005).

Study details: A 2-year, parallel arm, open-label, multicenter, randomized, prospective study of 57 postmenopausal women with osteoporosis who achieved osteopenia with denosumab.

Disclosure: The study was funded by institutional funds and the Hellenic Endocrine Society. Several authors reported receiving consulting or lecture fees from Amgen, which markets denosumab, as well as other pharmaceutical companies.

Citation:

Anastasilakis A et al. J Bone Miner Res. 2019 Aug 21. doi: 10.1002/jbmr.3853